Fluorine-18-α–Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer

This study has been completed.

First Received on April 20, 2007. No Changes Posted

Sponsor:	Gunma University
Information provided by:	Gunma University
ClinicalTrials.gov Identifier:	NCT00464282

Purpose

Objective: L-[3-18F]-α–methyltyrosine (FMT) is an amino-acid tracer for PET. We evaluated the diagnostic usefulness of 18F-FMT PET in non-small cell lung cancer (NSCLC) patients. Tumor uptake of 18F-FMT PET was compared with 18F-FDG PET and the correlation with L-type amino acid transporter 1 (LAT1) expression also investigated.

Method: Fifty patients with NSCLC were enrolled in this study, and a pair of PET study with 18F-FMT and 18F-FDG was performed. LAT1 expression and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical study.

Condition
Carcinoma, Non-Small-Cell Lung

Study Type:	Observational
Study Design:	Observational Model: Defined Population Primary Purpose: Screening Time Perspective: Longitudinal Time Perspective: Prospective

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer

U.S. FDA Resources

Further study details as provided by Gunma University:

Eligibility

Ages Eligible for Study:	8 Months to 2 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

proven or suspected non-small cell lung cancer

Exclusion Criteria:

uncontrolled diabetes mellitus

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00464282

Sponsors and Collaborators

Gunma University

Investigators

Principal Investigator:

kyoichi kaira, MD

Gunma Unversity Graduate School of Medicine

More Information

No publications provided by Gunma University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Kanai Y, Mori M, Endo K. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med. 2009 Nov;50(11):1770-6. Epub 2009 Oct 16.

ClinicalTrials.gov Identifier:	NCT00464282 History of Changes
Other Study ID Numbers:	Gunma 444
Study First Received:	April 20, 2007
Last Updated:	April 20, 2007
Health Authority:	Japan: Institutional Review Board

Keywords provided by Gunma University:

Fluorine–18-α–methyltyrosine,
Positron emission tomography,
Fluorodeoxyglucose
Lung cancer,

Amino acid transportor 1,
Ki-67
Proven or suspected non-small cell lung cancer were enrolled in the study

Additional relevant MeSH terms:

Carcinoma
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Carcinoma, Bronchogenic

Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on February 09, 2012